SHARE

Propanc Health Group Corp (OTCMKTS:PPCH) has acquired the services of Maxim Group as strategic advisor to the bio-medical company. Propanc works on the development of proprietary treatments for cancer patients. Currently, the company is studying the effects of PRP on cancer stem cells. The study is being carried out at the University of Jaen, in Spain. At the moment the company is just trying to find out what happens to the stem cells targeted by PRPs. Whether it would lead to another novel drug from PPCH, is yet to be known.

Maxim Group has been given the responsibilities to provide strategic planning and investment banking services to PPCH. Propanc plans to increase its shareholder value, which is in sub-penny land, through investment banking. This also includes efforts by the two companies to get PPCH listed on a national exchange. Maxim believes that Propanc has significant potential. It highlights that Propanc has a highly qualified management team, a large market for its products and a strong portfolio. All these factors combined, reflect on the true potential of PPCH, which Maxim would like to make the most of.

The company’s study targeting cancer stem cells is targeted at finding out the after effects of treating the cells with PRP. The study would be the latest in a series of studies by Propanc on tumor cells. One of the previously published studies by the company had revealed that PRP induces differentiation among tumor cells, but does that happen to CSCs as well.

CSCs are known to help in the formation of tumors and treatment resistance. Unfortunately, chemotherapy or radiotherapy is unable to rid the body of these cells, since they stay in a latent state. The outcome is a relapse of the deadly disease. However, it remains to be seen whether the study would lead to a new drug for the PPCH. If the findings of the study are positive, it can even lead to the development of a vaccine.

Propanc Health Group Corp (OTCMKTS:PPCH) closed at $0.0765, without reporting any change on May 28. The session saw 334.92 million shares change hands.

LEAVE A REPLY